Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-263-0 | CAS number: -
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 29.39 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 15
- Modified dose descriptor starting point:
- NOAEC
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 104.15 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 24
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- DMEL (Derived Minimum Effect Level)
- Value:
- 8.3 µg/cm²
- Most sensitive endpoint:
- sensitisation (skin)
DNEL related information
- Overall assessment factor (AF):
- 21
- Dose descriptor starting point:
- other: NOAEL
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Bisphenol F Diglycidylether (BPFDGE) was positive for the induction of dermal sensitization in the mouse Local Lymph Node Assay (LLNA). Based on an EC3 value of 0.7% BPFDGE is considered to be a strong dermal sensitizer. Following ECHA guidance this EC3 value is converted to an EC3 value of 175 ug/cm2 and is considered the LOAEL for the induction of dermal sensitization the mouse LLNA for BPFDGE.
- DERMAL - ACUTE LOCAL
Dose descriptor = EC3 of 0.7%; from a well described mouse LLNA study.
- Modification of dose descriptor:
= 0.7% * (250 ug/cm2/%)
dermal EC3 = 175 ug/cm2
- Adjustment factors (ECETOC Technical Report #86):
Criteria |
Adjustment Factor |
Allometric scaling - mouse |
7 |
Intraspecies - workers |
3 |
Overall Adjustment Factor |
21 |
- DNEL calculation
DNEL dermal = dermal NOAEL / (adjustment factors)
DNEL dermal = 175 ug/cm2 / (21)
DNEL dermal = 8.33 ug/cm2
The REACH Technical Guidance Document R.8 contains default assessment factors which should be applied to a modified dose descriptor in order to obtain a DNEL. These factors are multiplicative and can lead to a human chronic NAEL that is 100 or 200 fold lower than the equivalent rat subchronic NOAEL. However other guidance is available from ECETOC (2003), which supports smaller assessment factors to account for inter- and intra- species differences; leading to a human chronic NAEL that is only 24 to 40 -fold lower than an equivalent rat sub\chronic NOAEL. The ECETOC technical report includes scientific justification for the magnitude of these assessment factors, including:
· Although “residual” interspecies variability may remain following allometric scaling, this is largely accounted for in the default assessment factor proposed for intraspecies variability.
· Following analysis of the inherent variability in human toxicokinetic and toxicodynamic parameters, a difference of 3 (close to the 90th percentile) was considered appropriate to account for variability present in worker groups while a value of 5 (equivalent to the 95th percentile) was appropriate for the general population.
Section R.8.4.3.3 of the REACH Technical Guidance Document recognizes that the overall assessment factor applied to an experimental NOAEL when developing a DNEL is multiplicative in nature, and that “Care should be taken to avoid double counting several aspects when multiplying the individual factors.” Based on the information presented in ECETOC (2003) and summarized above, use of the standard defaults for inter- and intra- species variability contained in REACH Technical Guidance Document appears to result in “double counting”, and if used inappropriately, would lead to a large, conservative overall assessment factor. In order to retain the scientific credibility in its DNEL setting process, we will adopt the assessment factors proposed by ECETOC (2003) when developing DNELs.
- Critical NOAEL used = rabbit oral NOAEL 250 mg/kg/day (13-week oral subchronic repeat dose study – systemic)
- Absorption rates: 10% dermal, 100% oral, and 100% inhalation regardless of species
- DERMAL - SYSTEMIC
Dose descriptor = NOAEL of 250 mg/kg/day; from a well described 13-week oral subchronic repeat dose study.
- Modification of dose descriptor:
= oral NOAEL * (rat oral absorption rate / human dermal absorption rate)
= 250 * (100% / 10%)
dermal NOAEL = 2500 mg/kg/day
- Adjustment factors (ECETOC Technical Report #86):
Criteria |
Adjustment Factor |
Allometric scaling - rat |
4 |
Intraspecies - workers |
3 |
Subchronic study to Chronic |
2 |
Overall Adjustment Factor |
24 |
- DNEL calculation
DNEL dermal = dermal NOAEL / (adjustment factors)
DNEL dermal = 2500 mg/kg/day / (4 * 3 * 2)
DNEL dermal = 104.15 mg/kg/day
- INHALATION
Dose descriptor = NOAEL of 250 mg/kg/day; from a well described 13-week oral subchronic repeat dose study.
- Route-to-route extrapolation (calculation B.3 in ECHA Guidance R.8)
inhalatory NOAEC = oral NOAEL * (1/ sRV rat 8h) * (ABS oral / ABS inh) * (sRV human / wRV)
inhalatory NOAEC= 250 * (1/0.38) * (100/100) * (6.7/10)
inhalatory NOAEC = 440.79 mg/m3
- Adjustment factors (ECETOC Technical Report #86):
Criteria |
Adjustment Factor |
Allometric scaling - rat |
2.5 |
Intraspecies - workers |
3 |
Subchronic study to Chronic |
2 |
Overall Adjustment Factor |
15 |
- DNEL calculation
DNEL inhalation = inhalation NOAEC / (adjustment factors)
DNEL inhalation = 440.79 mg/m3 / (15)
DNEL inhalation = 29.39 mg/m3
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 8.7 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 25
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 62.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 40
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 6.25 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- Overall assessment factor (AF):
- 40
- Modified dose descriptor starting point:
- NOAEL
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The REACH Technical Guidance Document R.8 contains default assessment factors which should be applied to a modified dose descriptor in order to obtain a DNEL. These factors are multiplicative and can lead to a human chronic NAEL that is 100 or 200 fold lower than the equivalent rat subchronic NOAEL. However other guidance is available from ECETOC (2003), which supports smaller assessment factors to account for inter- and intra- species differences; leading to a human chronic NAEL that is only 24 to 40 -fold lower than an equivalent rat sub\chronic NOAEL. The ECETOC technical report includes scientific justification for the magnitude of these assessment factors, including:
· Although “residual” interspecies variability may remain following allometric scaling, this is largely accounted for in the default assessment factor proposed for intraspecies variability.
· Following analysis of the inherent variability in human toxicokinetic and toxicodynamic parameters, a difference of 3 (close to the 90th percentile) was considered appropriate to account for variability present in worker groups while a value of 5 (equivalent to the 95th percentile) was appropriate for the general population.
Section R.8.4.3.3 of the REACH Technical Guidance Document recognizes that the overall assessment factor applied to an experimental NOAEL when developing a DNEL is multiplicative in nature, and that “Care should be taken to avoid double counting several aspects when multiplying the individual factors.” Based on the information presented in ECETOC (2003) and summarized above, use of the standard defaults for inter- and intra- species variability contained in REACH Technical Guidance Document appears to result in “double counting”, and if used inappropriately, would lead to a large, conservative overall assessment factor. In order to retain the scientific credibility in its DNEL setting process, we will adopt the assessment factors proposed by ECETOC (2003) when developing DNELs.
Critical NOAEL used = rabbit oral NOAEL 250 mg/kg/day (13-week oral subchronic repeat dose study – systemic)
Absorption rates: 10% dermal, 100% oral, and 100% inhalation regardless of species
Dermal - Systemic
Dose descriptor = NOAEL of 250 mg/kg/day; from a well described 13-week oral subchronic repeat dose study.
Modification of dose descriptor
= dermal NOAEL * (rat oral absorption rate / human dermal absorption rate)
= 250 * (100% / 10%)
dermal NOAEL = 2500 mg/kg/day
Adjustment factors (ECETOC Technical Report #86):
Criteria |
Adjustment Factor |
Allometric scaling - rat |
4 |
Intraspecies – general population |
5 |
Subchronic study to Chronic |
2 |
Overall Adjustment Factor |
40 |
DNEL calculation
DNEL dermal = dermal NOAEL / (adjustment factors)
DNEL dermal = 2500 mg/kg/day / (4 * 5 * 2)
DNEL dermal = 62.50 mg/kg/day
Inhalation
Dose descriptor = NOAEL of 250 mg/kg/day; from a well described 13-week oral subchronic repeat dose study.
Route-to-route extrapolation (calculation B.3 in ECHA Guidance R.8)
inhalatory NOAEC = oral NOAEL * (1/ sRV rat 24h) * (ABS oral / ABS inh)
inhalatory NOAEC= 250 * (1/1.15) * (100/100)
inhalatory NOAEC = 217.39 mg/m3
Adjustment factors (ECETOC Technical Report #86):
Criteria |
Adjustment Factor |
Allometric scaling - rat |
2.5 |
Intraspecies – General Population |
5 |
Subchronic study to Chronic |
2 |
Overall Adjustment Factor |
25 |
DNEL calculation
DNEL inhalation = inhalation NOAEC / (adjustment factors)
DNEL inhalation = 217.39 mg/m3 / (25)
DNEL inhalation = 8.70 mg/m3
Oral
Dose descriptor = NOAEL of 250 mg/kg/day; from a well described oral development toxicity study
Modification of dose descriptor: Not required
Adjustment factors (ECETOC Technical Report #86):
Criteria |
Adjustment Factor |
Allometric scaling - rat |
4 |
Intraspecies – General Population |
5 |
Subchronic study to Chronic |
2 |
Overall Adjustment Factor |
40 |
DNEL calculation
DNEL oral = oral NOAEL / (adjustment factors)
DNEL oral = 250 mg/kg/day / (40)
DNEL oral = 6.25 mg/kg/day
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
